The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Does visceral fat area (VFA) have predictive value for hypertension (HTN) and progression-free survival (PFS) in patients (pts) with stage IV NSCLC receiving bevacizumab (Beva)?
O. Mir
Consultant or Advisory Role - Roche (U); SERVIER (U)
R. Coriat
No relevant relationships to disclose
S. Ropert
Consultant or Advisory Role - Roche (U)
J. Chapron
No relevant relationships to disclose
P. Boudou-Rouquette
No relevant relationships to disclose
J. Durand
Consultant or Advisory Role - Merck (U)
T. Bui
No relevant relationships to disclose
D. Dusser
No relevant relationships to disclose
F. Goldwasser
Consultant or Advisory Role - Amgen (U); Bayer (U); Pfizer (U)